157 related articles for article (PubMed ID: 28941658)
1. Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
Barber EL; Rossi EC; Gehrig PA
Gynecol Oncol; 2017 Dec; 147(3):607-611. PubMed ID: 28941658
[TBL] [Abstract][Full Text] [Related]
2. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
4. Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study.
Leiserowitz GS; Lin JF; Tergas AI; Cliby WA; Bristow RE
Int J Gynecol Cancer; 2017 May; 27(4):675-683. PubMed ID: 28328580
[TBL] [Abstract][Full Text] [Related]
5. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
6. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.
Fagö-Olsen CL; Ottesen B; Kehlet H; Antonsen SL; Christensen IJ; Markauskas A; Mosgaard BJ; Ottosen C; Soegaard CH; Soegaard-Andersen E; Hoegdall C
Gynecol Oncol; 2014 Feb; 132(2):292-8. PubMed ID: 24321400
[TBL] [Abstract][Full Text] [Related]
7. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL
JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD005343. PubMed ID: 34328210
[TBL] [Abstract][Full Text] [Related]
10. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
[TBL] [Abstract][Full Text] [Related]
11. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
[TBL] [Abstract][Full Text] [Related]
12. The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery.
Yang SP; Chen JX; Xu JY; Lei J; Wu SG; Zhou J
Cancer Med; 2022 Jul; 11(14):2836-2845. PubMed ID: 35274489
[TBL] [Abstract][Full Text] [Related]
13. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
[TBL] [Abstract][Full Text] [Related]
15. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
[TBL] [Abstract][Full Text] [Related]
16. Unplanned hospitalizations in a racially and ethnically diverse population of women receiving chemotherapy for epithelial ovarian cancer.
Dioun S; Jorgensen JR; Miller EM; Tymon-Rosario J; Xie X; Xue X; Kuo DY; Nevadunsky NS
Gynecol Oncol; 2018 Oct; 151(1):134-140. PubMed ID: 30149897
[TBL] [Abstract][Full Text] [Related]
17. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
Persenaire C; Pyrzak A; Barber EL
J Minim Invasive Gynecol; 2022 Mar; 29(3):375-384. PubMed ID: 34648931
[TBL] [Abstract][Full Text] [Related]
18. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
Worley MJ; Guseh SH; Rauh-Hain JA; Williams KA; Muto MG; Feltmate CM; Berkowitz RS; Horowitz NS
Gynecol Oncol; 2013 Apr; 129(1):69-73. PubMed ID: 23375727
[TBL] [Abstract][Full Text] [Related]
19. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Coleridge SL; Bryant A; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD005343. PubMed ID: 33543776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
